Big pharma company Eli Lilly (LLY -2.40%) faces allegations of bribing medical doctors in China, just weeks after similar claims arose against its peers GlaxoSmithKline and Sanofi. In the following video, taken from The Motley Fool's health-care show, analysts David Williamson and Max Macaluso discuss this story and the potential impact of these claims on investors.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
One More Big Pharma Bribery Scandal?
By Max Macaluso and Dave Williamson
–
Aug 27, 2013 at 6:30PM
NYSE: LLY
Eli Lilly
Market Cap
$735B
Today's Change
(-2.40%) -$19.04
Current Price
$776.08
Price as of June 27, 2025, 3:58 p.m. ET
Another drugmaker faces claims of misconduct in China.
David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Eli Lilly
LLY
$776.08
(-2.40%)
$-19.04
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Which Stock Will Dominate the Weight Management Market Through 2030?
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
1 Growth Stock Down 9% to Buy Right Now
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.